INOVIO Pharmaceuticals, Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023. INOVIO is a clinical-stage biotechnology company developing DNA medicines and its CELLECTRA delivery technology. It has no approved products and reported no product-sales revenue.
Financial performance and position
| Metric | Q1 2023 | Q1 2022 / comparison |
|---|---|---|
| Revenue | $115,000 | $199,000; down about 42% |
| Research and development | $30.2 million | $56.0 million; down 46% |
| General and administrative | $13.9 million | $16.0 million; down 13% |
| Net loss | $40.6 million | $79.1 million |
| Loss per share, basic and diluted | $0.16 | $0.36 |
| Net cash used in operating activities | $36.7 million | $61.9 million |
| Cash, cash equivalents and short-term investments | $223.8 million at March 31 | $253.0 million at December 31, 2022 |
| Working capital | $178.7 million at March 31 | $218.4 million at December 31, 2022 |
At March 31, cash and cash equivalents were $28.2 million and short-term investments were $195.5 million. Total liabilities were $67.4 million. Convertible notes had a net carrying amount of $16.4 million, bear 6.5% interest, and mature March 1, 2024; contractual payments, including interest, total $17.5 million. Operating lease liabilities totaled $14.8 million. The filing does not report a meaningful product gross margin because the company has no product sales.
Material changes and notable items
- Operating expenses fell year over year, primarily from reduced INO-4800/COVID-19 and CELLECTRA device spending, lower VGX-3100 costs, and lower compensation and stock-based compensation. Lower grant reimbursements partly offset the R&D expense reduction.
- Interest income rose to $2.2 million from $0.7 million. Investment-related results were volatile: Q1 included a $3.2 million unrealized gain on available-for-sale equity securities and $2.4 million of other expense, primarily realized losses on short-term investments.
- INOVIO completed the securities class-action settlement: insurers funded the $30.0 million cash component, and the company issued 9.1 million shares valued at $14.0 million. The settlement shares increased outstanding common shares.
- A January 2023 reorganization reduced headcount by approximately 24 employees, or 11% of full-time staff. INOVIO recorded a one-time $1.1 million pre-tax charge and estimated annual savings of approximately $4.3 million.
Outlook, management commentary and risks
- Management said current cash and short-term investments should fund planned operations for at least 12 months from the financial statement issuance date. Separately, it expects the July 2022 and January 2023 cost reductions and reduced internal COVID-19 spending to extend cash runway into Q1 2025, assuming no further capital raises. These are estimates, not a guarantee; the company expects continued losses and will need additional capital to advance and commercialize candidates.
- Management cited Q1/early 2023 Phase 1/2 INO-3107 data showing a statistically significant reduction in median surgeries for HPV-associated recurrent respiratory papillomatosis (RRP). The candidate remains investigational and requires further development and regulatory review.
- INOVIO discontinued internally funded development of INO-4800 as a COVID-19 booster in Q4 2022 and reported no active company-run INO-4800 clinical trials. Advaccine may continue development in China and other Asian territories, but approval or commercial revenue is uncertain. INOVIO and CEPI also discontinued development of candidates targeting Lassa fever and MERS in November 2022.
- Key risks include clinical, regulatory and manufacturing uncertainty; dependence on collaborators, grants and contract manufacturers; need for additional financing and potential shareholder dilution; and exposure to investment-market, interest-rate and bank-deposit risks. Available-for-sale securities had $6.5 million of unrealized losses at quarter-end, which the company attributed primarily to interest-rate changes rather than credit losses.
- Litigation remains relevant. The securities class action was settled, while shareholder derivative matters were subject to a proposed settlement process. VGXI and GeneOne disputes remained pending, with no trial dates reported.
- Subsequent to quarter-end, Nasdaq notified INOVIO on May 4, 2023 that its share price failed the $1.00 minimum bid requirement. The initial compliance period ran to October 31, 2023; delisting remained possible if compliance was not regained.
Important facts for investors to verify
- Whether the projected cash runway into Q1 2025 remains achievable given operating cash use, clinical spending and any new financing.
- INO-3107 trial progress, endpoint and regulatory requirements, and whether early results are confirmed in larger studies.
- Advaccine’s development plans and any regulatory or commercial milestones for INO-4800; no such approval or revenue is assured.
- Potential share dilution from future financing, equity-plan awards, or other issuances, and the status of Nasdaq listing compliance.
- Developments in the derivative, VGXI and GeneOne litigation and any resulting financial or operational effects.